Key Points
- Director Melissa Epperly sold 17,750 Roivant Sciences shares at an average price of $36.10, generating $640,775. The Rule 10b5-1 transaction reduced her stake by 54.27% to 14,954 shares.
- Roivant shares opened at $35.78, with a market capitalization of approximately $25.84 billion and a 12-month trading range of $15.25 to $42.50.
- Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $45.64; institutional investors own 64.76% of the stock.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) Director Melissa Epperly sold 17,750 shares of the firm's stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $36.10, for a total value of $640,775.00. Following the transaction, the director owned 14,954 shares in the company, valued at $539,839.40. This represents a 54.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Roivant Sciences Trading Up 0.2%
Shares of NASDAQ ROIV opened at $35.78 on Tuesday. The stock has a 50 day moving average of $36.61 and a two-hundred day moving average of $32.65. The stock has a market cap of $25.84 billion, a P/E ratio of -67.51 and a beta of 1.10. Roivant Sciences Ltd. has a twelve month low of $15.25 and a twelve month high of $42.50.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. The company had revenue of $1.44 million for the quarter, compared to the consensus estimate of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. As a group, research analysts predict that Roivant Sciences Ltd. will post -2 earnings per share for the current year.
Analyst Upgrades and Downgrades
ROIV has been the topic of several recent research reports. TD Cowen boosted their price objective on shares of Roivant Sciences from $50.00 to $55.00 and gave the company a "buy" rating in a research note on Wednesday, September 9th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Roivant Sciences in a report on Thursday, September 24th. HC Wainwright boosted their price target on shares of Roivant Sciences from $41.00 to $47.00 and gave the stock a "buy" rating in a research note on Tuesday, September 8th. Jefferies Financial Group increased their price target on shares of Roivant Sciences from $42.00 to $52.00 and gave the stock a "buy" rating in a report on Tuesday, September 8th. Finally, Stifel Nicolaus began coverage on shares of Roivant Sciences in a research report on Wednesday, September 16th. They issued a "buy" rating and a $51.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $45.64.
Get Our Latest Report on Roivant Sciences
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Waverly Advisors LLC boosted its stake in shares of Roivant Sciences by 2.3% in the second quarter. Waverly Advisors LLC now owns 12,869 shares of the company's stock valued at $455,000 after purchasing an additional 291 shares during the period. Fifth Third Bancorp increased its stake in Roivant Sciences by 8.7% during the 1st quarter. Fifth Third Bancorp now owns 4,686 shares of the company's stock worth $130,000 after buying an additional 376 shares during the period. Bessemer Group Inc. increased its stake in Roivant Sciences by 21.8% during the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company's stock worth $69,000 after buying an additional 441 shares during the period. Fifth Third Wealth Advisors LLC lifted its holdings in Roivant Sciences by 4.6% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company's stock worth $282,000 after buying an additional 445 shares in the last quarter. Finally, Versant Capital Management Inc boosted its position in Roivant Sciences by 13.9% in the 2nd quarter. Versant Capital Management Inc now owns 3,995 shares of the company's stock valued at $141,000 after buying an additional 487 shares during the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.
About Roivant Sciences
(
Get Free Report)
Roivant Sciences Ltd. (NASDAQ:ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with serious or underserved diseases. The company operates through a network of subsidiary companies, known as “Vants,” each dedicated to specific therapeutic areas, drug candidates or commercial opportunities.
Roivant's research and development activities have included treatments for immune-mediated diseases, rare disorders, oncology and conditions affecting the nervous system.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
